{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:07:15Z","timestamp":1791547635716,"version":"4.3.4"},"reference-count":25,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100018896","name":"Sylvester Comprehensive Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018896","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ijgc.2025.102879","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T05:02:32Z","timestamp":1766120552000},"page":"102879","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Improved progression-free survival with mirvetuximab and bevacizumab in platinum-resistant ovarian cancer: a retrospective real-world analysis"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-5445-8198","authenticated-orcid":false,"given":"Jill N.T.","family":"Roberts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Courel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0257-7327","authenticated-orcid":false,"given":"Matthew P.","family":"Schlumbrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navya","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5559-0704","authenticated-orcid":false,"given":"Abdulrahman K.","family":"Sinno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ijgc.2025.102879_bib1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.23.01771","article-title":"Treatment approaches for platinum-resistant ovarian cancer","volume":"42","author":"St Laurent","year":"2024","journal-title":"J Clin Oncol."},{"issue":"2","key":"10.1016\/j.ijgc.2025.102879_bib2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.critrevonc.2013.08.017","article-title":"Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer","volume":"89","author":"Colombo","year":"2013","journal-title":"Crit Rev Oncol Hematol."},{"issue":"12","key":"10.1016\/j.ijgc.2025.102879_bib3","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1080\/14737140.2017.1398088","article-title":"Optimizing treatment in recurrent epithelial ovarian cancer","volume":"17","author":"Corrado","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.ijgc.2025.102879_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1258228","article-title":"Overcoming the challenges of drug development in platinum-resistant ovarian cancer","volume":"13","author":"Eskander","year":"2023","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102879_bib5","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/ijc.21712","article-title":"The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander?","volume":"119","author":"Kelemen","year":"2006","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102879_bib6","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ygyno.2007.11.020","article-title":"Folate receptor alpha as a tumor target in epithelial ovarian cancer","volume":"108","author":"Kalli","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2025.102879_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1254532","article-title":"Therapeutic strategies targeting folate receptor \u03b1 for ovarian cancer","volume":"14","author":"Mai","year":"2023","journal-title":"Front Immunol"},{"issue":"13","key":"10.1016\/j.ijgc.2025.102879_bib9","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1200\/JCO.22.01900","article-title":"Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study","volume":"41","author":"Matulonis","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102879_bib10","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2217\/fon-2017-0379","article-title":"A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer","volume":"14","author":"Moore","year":"2018","journal-title":"Future Oncol."},{"issue":"23","key":"10.1016\/j.ijgc.2025.102879_bib11","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N Engl J Med."},{"issue":"13","key":"10.1016\/j.ijgc.2025.102879_bib12","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ijgc.2025.102879_bib13","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1093\/annonc\/mdx228","article-title":"Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial","volume":"28","author":"Bamias","year":"2017","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102879_bib14","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ygyno.2020.01.037","article-title":"Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer","volume":"157","author":"O\u2019Malley","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2025.102879_bib15","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ygyno.2023.01.020","article-title":"Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer","volume":"170","author":"Gilbert","year":"2023","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102879_bib16","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.trecan.2023.01.003","article-title":"Antibody-drug conjugates: in search of partners of choice","volume":"9","author":"Fuentes-Antr\u00e1s","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ijgc.2025.102879_bib17","article-title":"Bevacizumab in ovarian cancer therapy: current advances, clinical challenges, and emerging strategies","volume":"13","author":"Zhang","year":"2025","journal-title":"Front Bioeng Biotechnol"},{"issue":"12","key":"10.1016\/j.ijgc.2025.102879_bib18","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1158\/1078-0432.CCR-11-3000","article-title":"Bevacizumab-induced alterations in vascular permeability and drug delivery: a novel approach to augment regional chemotherapy for in-transit melanoma","volume":"18","author":"Turley","year":"2012","journal-title":"Clin Cancer Res."},{"issue":"13","key":"10.1016\/j.ijgc.2025.102879_bib19","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1158\/1078-0432.CCR-07-0278","article-title":"Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy","volume":"13","author":"Dickson","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"5706","key":"10.1016\/j.ijgc.2025.102879_bib20","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.ijgc.2025.102879_bib21","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2147\/IJN.S470219","article-title":"Tumor microenvironment responsive key nanomicelles for effective against invasion and metastasis in ovarian cancer using mice model","volume":"20","author":"Liu","year":"2025","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.ijgc.2025.102879_bib22","author":"Berman"},{"key":"10.1016\/j.ijgc.2025.102879_bib23","unstructured":"Shaffer AT. Targeting FR\u237a enters a new era in ovarian cancer and beyond. OncLive. Accessed February 1 2025. https:\/\/www.onclive.com\/view\/targeting-fr-enters-a-new-era-in-ovarian-cancer-and-beyond."},{"issue":"suppl 16","key":"10.1016\/j.ijgc.2025.102879_bib24","article-title":"GLORIOSA: a randomized, open-label, phase 3 study of mirvetuximab soravtansine with bevacizumab vs. bevacizumab as maintenance in platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer","volume":"41","author":"O\u2019Malley","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijgc.2025.102879_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.09.1994","article-title":"819TiP FONTANA: a phase I\/IIa study of AZD5335 as monotherapy and in combination with anti-cancer agents in patients with solid tumours","volume":"34","author":"Meric-Bernstam","year":"2023","journal-title":"Ann Oncol"},{"issue":"suppl 16","key":"10.1016\/j.ijgc.2025.102879_bib26","article-title":"Initial results from a first-in-human phase 1 study of LY4170156, an ADC targeting folate receptor alpha (FR\u03b1), in advanced ovarian cancer and other solid tumors","volume":"43","author":"Ray-Coquard","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25020031?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25020031?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T09:34:17Z","timestamp":1780306457000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X25020031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1048891X25020031"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.102879","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improved progression-free survival with mirvetuximab and bevacizumab in platinum-resistant ovarian cancer: a retrospective real-world analysis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.102879","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102879"}}